ACRS Company Profile and Key Details
NASDAQ : ACRS
Aclaris Therapeutics
$4.84
0.34+7.56%
At Close 4:00 PM72.81
BESG ScoreESG Rating
Price Chart
Stock Price Today
Aclaris Therapeutics, Inc. (ACRS) stock surged +7.56%, trading at $4.84 on NASDAQ, up from the previous close of $4.50. The stock opened at $4.55, fluctuating between $4.50 and $4.91 in the recent session.
Stock Snapshot
4.5
Prev. Close
583.68M
Market Cap
4.5
Day Low
-8.64
P/E Ratio
-0.56
EPS (TTM)
-1.12
Cash Flow per Share
4.55
Open
120.6M
Number of Shares
4.91
Day High
85.19%
Free Float in %
2.22
Book Value
1.82M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 22, 2026 | 4.55 | 4.93 | 4.50 | 4.84 | 1.82M |
| Jun 18, 2026 | 4.56 | 4.58 | 4.37 | 4.50 | 4.32M |
| Jun 17, 2026 | 4.32 | 4.52 | 4.30 | 4.42 | 1.19M |
| Jun 16, 2026 | 4.37 | 4.43 | 4.25 | 4.34 | 1.09M |
| Jun 15, 2026 | 4.43 | 4.55 | 4.26 | 4.36 | 1.68M |
| Jun 12, 2026 | 4.39 | 4.53 | 4.29 | 4.32 | 1.11M |
| Jun 11, 2026 | 4.12 | 4.39 | 4.07 | 4.37 | 818.75K |
| Jun 10, 2026 | 4.29 | 4.39 | 4.08 | 4.10 | 1.22M |
| Jun 09, 2026 | 4.41 | 4.47 | 4.22 | 4.30 | 1.02M |
| Jun 08, 2026 | 4.42 | 4.49 | 4.29 | 4.36 | 1.46M |
| Jun 05, 2026 | 4.69 | 4.70 | 4.33 | 4.36 | 928.95K |
| Jun 04, 2026 | 4.46 | 4.77 | 4.42 | 4.71 | 1.07M |
| Jun 03, 2026 | 4.63 | 4.65 | 4.40 | 4.42 | 1.56M |
| Jun 01, 2026 | 4.53 | 4.55 | 4.32 | 4.34 | 2.23M |
| May 29, 2026 | 4.61 | 4.68 | 4.50 | 4.55 | 1.18M |
| May 28, 2026 | 4.60 | 4.63 | 4.55 | 4.57 | 640.78K |
| May 27, 2026 | 4.51 | 4.68 | 4.50 | 4.58 | 682.63K |
| May 26, 2026 | 4.52 | 4.62 | 4.47 | 4.51 | 718.19K |
| May 22, 2026 | 4.54 | 4.60 | 4.50 | 4.52 | 627.7K |
| May 21, 2026 | 4.50 | 4.58 | 4.45 | 4.54 | 475.3K |
Contact Details
About Company
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Company Information
| Employees | 61 |
| Beta | 0.8 |
| Sales or Revenue | $31.25M |
| 5Y Sales Change% | 0.46% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
26.03+2.97%
argenx SE$903.75REGN2.56+0.42%
Regeneron Pharmaceuticals, Inc.$612.50UTHR1.70998+0.32%
United Therapeutics Corporation$538.30MDGL7.13+1.41%
Madrigal Pharmaceuticals, Inc.$512.88VRTX15.16+3.36%
Vertex Pharmaceuticals Incorporated$466.79KRYS-4.63-1.33%
Krystal Biotech, Inc.$343.43KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX21.08+7.47%
Praxis Precision Medicines, Inc.$303.39ALNY8.32+2.99%
Alnylam Pharmaceuticals, Inc.$286.41LGND-12.71-4.62%
Ligand Pharmaceuticals Incorporated$262.17Company Overview
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) closed at $4.84 USD, gaining $0.34 (7.56%) from the previous close of $4.50. The stock is currently mid-range between its 52-week high and low $1.38 and $5.15. With a market capitalization of about $583.68 million, Aclaris Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.80). Key stats such as the average daily volume over the past year has been around 1.43 million shares, in line with its 52-week average. Headquartered in Wayne, PA, Aclaris Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Neal S. Walker, the company employs approximately 61 people and listed since October 06, 2015. Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions.
Technical Performance
ACRS has shown sold momentum, gaining 66.54% over the past week and 133.16% over the past quarter, though year-to-date performance is up 47.18%. Short-term trend indicators are bearishly aligned (SMA20 -7.6%, SMA50 -3.99%, SMA200 39.79%). The stock’s 14-day RSI is 43.46 (neutral), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -35.99% below its high and over 198.1% above its low. Average 10-day trading volume of 2.02 million shares is slightly above the 3-month average of 1.44 million, indicating heightened recent market interest.
Valuation Metrics
Aclaris Therapeutics, Inc. trades at a P/E ratio of -8.44, slightly below the S&P 500 average, with a price-to-sales ratio of 68.1 and a price-to-book ratio of 4.24 trading at moderately above to book value. The P/FCF stands at -10.9, also above market averages.
Dividend & Fair Value
Aclaris Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.96. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Aclaris Therapeutics, Inc. generated EPS of -$1.38 over the past year. Five-year average earnings growth is 15.24%. Wall Street analysts project EPS growth of 27.1% annually over the next five years. The latest quarter delivered EPS of -$0.15. The next quarter is forecast at -$0.14. Next year's EPS is expected at $18.80. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $6.00. The high target offers 230.58% upside. The low target suggests 23.97% downside. The mean target is $12.45. This offers 157.23% upside. Aclaris Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -6.25%. The prior quarter beat by 6.67%. Over the last six quarters, Apple has recorded several small beats. These include 11.11% in February 27, 2025.
Shareholding & Insider Activity
Aclaris Therapeutics, Inc. has 139.66 million shares outstanding. The public float is 113.14 million shares, elevated short interest at 6.61% of float. This equals 8.08 million shares. The short ratio is 6.84 days. Institutional investors hold 82.54% of the float. Insiders own 2.71%. Leonard Braden Michael holds 13.95 million shares, Walker Neal has 1.27 million shares and Flynn James E has 964.10 thousand shares. Over the past six months, insider transactions show net selling. They sold 300.00 thousand shares across 1 transactions.
Financial & Profitability Overview
On valuation metrics, Aclaris Therapeutics trades at a P/E of -8.44, P/S of 68.10 and P/B of 4.24. The current ratio is 4.03 and quick ratio is 4.03. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -2505.56 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -26.30.
Quarterly Financial Highlights
The company ended the quarter with $119.11M in cash and short-term investments, a total debt of $426.00K, and net debt of - $39.45M. Total assets were $197.41M, with equity of $157.18M. Financials further reflected weakness, with operating cash flow of - $78.33M, free cash flow of - $79.63M, and capital expenditures of - $1.31M.
Price Forecast & Outlook
Our AI price prediction model suggests that Aclaris Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.89%, with price expected at $4.70 by July 06, 2026, within a range of $4.50 to $4.92 3-Month Outlook: Projected fall of -54.55%, reaching $2.20 by September 16, 2026, with a range of $1.96 to $2.36. 1-Year Outlook: Projected gain of 377.89%, with price at $23.13 by June 22, 2027, within a range of $25.20 to $27.91.
Key Takeaways
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) shares are up 47.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Aclaris Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.44. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $25.82, suggesting 433.47% upside. Our AI forecast model points to short-term weakness (-2.89% over two weeks), a medium-term fall (-54.55% over three months), and a longer-term gain (377.89% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Aclaris Therapeutics, Inc. (ACRS) stock price?
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) stock price is $4.84 in the last trading session. During the trading session, ACRS stock reached the peak price of $4.91 while $4.50 was the lowest point it dropped to. The percentage change in ACRS stock occurred in the recent session was 7.56% while the dollar amount for the price change in ACRS stock was $0.34.
ACRS's industry and sector of operation?
The NASDAQ listed ACRS is part of Biotechnology industry that operates in the broader Healthcare sector. Aclaris Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ACRS?
Mr. Matthew Rothman J.D.
Gen. Counsel & Corporation Sec.
Dr. Gail Cawkwell M.D., Ph.D.
Chief Medical Officer
Mr. Frank Ruffo
Co-Founder, Chief Financial Officer , Sec. & Treasurer
Mr. Robert A. Doody Jr.
Vice President of Investor Relations
Dr. Paul S. Changelian Ph.D.
Senior Vice President of Biology
Dr. Neal S. Walker D.O.
Co-Founder & Chairman
Dr. Jon Jacobsen Ph.D.
Senior Vice President of Chemistry
Dr. Douglas J. Manion Frcp(C), M.D.
Chief Executive Officer, Pres & Director
Dr. Joseph Monahan
Chief Scientific Officer
Mr. James Loerop
Chief Bus. Officer
Dr. Ian Anderson Ph.D.
Executive Vice President of Translational R&D
Mr. Gary A. DeCrescenzo
Senior Vice President of Pharmaceutical R&D
Mr. Kevin Balthaser
Chief Financial Officer
Dr. Joseph Monahan Ph.D.
Chief Scientific Officer
Gen. Counsel & Corporation Sec.
Dr. Gail Cawkwell M.D., Ph.D.
Chief Medical Officer
Mr. Frank Ruffo
Co-Founder, Chief Financial Officer , Sec. & Treasurer
Mr. Robert A. Doody Jr.
Vice President of Investor Relations
Dr. Paul S. Changelian Ph.D.
Senior Vice President of Biology
Dr. Neal S. Walker D.O.
Co-Founder & Chairman
Dr. Jon Jacobsen Ph.D.
Senior Vice President of Chemistry
Dr. Douglas J. Manion Frcp(C), M.D.
Chief Executive Officer, Pres & Director
Dr. Joseph Monahan
Chief Scientific Officer
Mr. James Loerop
Chief Bus. Officer
Dr. Ian Anderson Ph.D.
Executive Vice President of Translational R&D
Mr. Gary A. DeCrescenzo
Senior Vice President of Pharmaceutical R&D
Mr. Kevin Balthaser
Chief Financial Officer
Dr. Joseph Monahan Ph.D.
Chief Scientific Officer
How ACRS did perform over past 52-week?
ACRS's closing price is 260.39% higher than its 52-week low of $1.38 where as its distance from 52-week high of $5.15 is -6.02%.
How many employees does ACRS have?
Number of ACRS employees currently stands at 61.
Link for ACRS official website?
Official Website of ACRS is: https://www.aclaristx.com
How do I contact ACRS?
ACRS could be contacted at phone 484 324 7933 and can also be accessed through its website. ACRS operates from 640 Lee Road, Wayne, PA 19087, United States.
How many shares of ACRS are traded daily?
ACRS stock volume for the day was 1.82M shares. The average number of ACRS shares traded daily for last 3 months was 1.43M.
What is the market cap of ACRS currently?
The market value of ACRS currently stands at $583.68M with its latest stock price at $4.84 and 120.6M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep